NCT04232826 - A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

January 1, 2021

Study Completion Date

November 1, 2022

Conditions

Diffuse Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

single dose of CNCT19

"Dose A: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 4.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"

Trial Locations (2)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

Unknown

Henan Cancer Hospital, Zhengzhou